Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.9179 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 1 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.9179 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 1 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.9179 | 0.9179 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 1 | 1 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0023 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.9179 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 1 | 1 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 1 | 1 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.9179 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.9179 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 1 | 1 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 1 | 1 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 1 | 1 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 1 | 1 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 2.2387 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.4668 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 100 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of DNA Polymerase Beta. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.